Acquisition of ePocrates for $293 million (3.1x multiple).
This document is page 39 of a confidential investment memorandum or fund report stamped by House Oversight. It details specific healthcare investment themes including Care Coordination, Clinical Error Reduction, and Analytics/Data-Driven Personalization, highlighting portfolio companies such as TigerText, ePocrates, iRhythm Technologies, and Treato. The document notes the financial success of ePocrates (acquired for $293 million) and attributes several companies to a fund designated as 'NLV-II'.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein financial record